NEW YORK (GenomeWeb News) - Clarient has acquired an exclusive license to Health Discovery Corporation’s prostate cancer marker and plans to develop and commercialize a test based on the marker, HDC said today.
Under the agreement, HDC will receive a 30 percent royalty payment for all prostate cancer tests Clarient performs for third parties using the technology.
Clarient said the four-gene test could enable early detection of prostate cancer and help doctors make better informed decisions about treatment strategies.
Clarient said it plans to immediately start validation programs and then push the test into clinical studies and toward regulatory submission.
HDC CEO Stephen Barnhill estimated that the current market for prostate cancer screening is more than $350 million per year and presents a “tremendous market opportunity” for the firm.